Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers show how bacteria responsible for strep throat can be used to fight colon cancer

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer.

21 May 2014

New antibody can improve quality of life for individuals with asthma

Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.

20 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

New ultra-sensitive nano-chip capable of detecting cancer at early stages

The majority of cancers are detected on the macroscopic level, when the tumor is already composed of millions of cancer cells and the disease is starting to advance into a more mature phase.

19 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Kymab raises US$40 million in Series B financing

Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.

16 May 2014

Shark antibodies reveal evolutionary principles of immunoglobulins

Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.

15 May 2014

Scripps Research Institute scientists show AIDS vaccine could work against changeable site on HIV

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus-thanks to the diversity of targets the site presents to the human immune system.

15 May 2014

Scientist wins 2014 Maurice Hilleman/Merck Award for developing vaccine against meningococcal disease

Dan Granoff, MD, of UCSF Benioff Children's Hospital Oakland's research arm CHORI, has been named the 2014 Maurice Hilleman/Merck Award Laureate by the American Society for Microbiology (ASM).

15 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone.

14 May 2014

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.

14 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

14 May 2014

Antibody News and Research

Further Reading

Researchers show how bacteria responsible for strep throat can be used to fight colon cancer

New antibody can improve quality of life for individuals with asthma

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

BioLineRx announces financial results for Q1 2014, provides operational update

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

New ultra-sensitive nano-chip capable of detecting cancer at early stages

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Kymab raises US$40 million in Series B financing

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

Shark antibodies reveal evolutionary principles of immunoglobulins

Scripps Research Institute scientists show AIDS vaccine could work against changeable site on HIV

Scientist wins 2014 Maurice Hilleman/Merck Award for developing vaccine against meningococcal disease

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo